Premium
Screening for potential serum‐based proteomic biomarkers for human type 2 diabetes mellitus using MALDI‐TOF MS
Author(s) -
Meng Qiutao,
Ge Siqi,
Yan Wenhua,
Li Ruisheng,
Dou Jingtao,
Wang Haibing,
Wang Baoan,
Ma Qingwei,
Zhou Yong,
Song Manshu,
Yu Xinwei,
Wang Hao,
Yang Xinghua,
Liu Fen,
Alzain Mohamed Ali,
Yan Yuxiang,
Zhang Ling,
Wu Lijuan,
Zhao Feifei,
He Yan,
Guo Xiuhua,
Chen Feng,
Xu Weizhuo,
Garcia Monique,
Me Desmond,
Wang Youxin,
Mu Yiming,
Wang Wei
Publication year - 2017
Publication title -
proteomics – clinical applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 54
eISSN - 1862-8354
pISSN - 1862-8346
DOI - 10.1002/prca.201600079
Subject(s) - type 2 diabetes mellitus , peptide , medicine , diabetes mellitus , bioinformatics , computational biology , chemistry , biology , endocrinology , biochemistry
Background Type 2 diabetes mellitus (T2DM) is a complex, pandemic disease contributing towards the global burden of health issues. To date, there are no simple clinical tests for the early detection of T2DM. Method To identify potential peptide biomarkers for such applications, 406 sera of T2DM patients ( n = 206) and healthy controls ( n = 200) are analyzed by using MALDI‐TOF MS with a cross‐sectional case‐control design. Result Six peptides (peaks m/z 1452.9, 1692.8, 1946.0, 2115.1, 2211.0 and 4053.6) are identified as candidate biomarkers for T2DM. A diagnostic model constructed with six peptides is able to discriminate T2DM patients from healthy controls, with an accuracy of 82.20%, sensitivity of 82.50%, and specificity of 77.80% in the validation set. Peptide peaks m/z 1452.9 and 1692.8 are identified as fragments of the complement C3f, while peptide peaks m/z 1946.0, 2115.1, and 2211.0 are identified as the fragments of kininogen 1 isoform 1 precursor. Conclusion This study reinforces proteomic analyses as a potential technique for defining significant clinical peptide biomarkers, providing a simple and convenient diagnostic model for T2DM in clinical examination.